ADC Therapeutics SA EBITDA Margin 2019-2021 | ADCT

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for ADC Therapeutics SA (ADCT) over the last 10 years. The current EBITDA margin for ADC Therapeutics SA as of September 30, 2021 is .
ADC Therapeutics SA EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.011B $0.002B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88